MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13195-024-01395-x

Медицинская библиотека · Alzheimer's research & therapy · 2024

Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants.

Morales Clarissa D, Cotton-Samuel Dejania, Lao Patrick J, Chang Julia F, Pyne Jeffrey D, Alshikho Mohamad J, Lippert Rafael V, Bista Kelsang, Hale Christiane, Edwards Natalie C, Igwe Kay C, Deters Kacie, Zimmerman Molly E, Brickman Adam M

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Secondary prevention clinical trials for Alzheimer's disease (AD) target amyloid accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent other pathophysiological processes, such as small vessel cerebrovascular disease, account for participant performance on the primary cognitive outcomes in those trials. White matter hyperintensities are areas of increased signal on T2-weighted magnetic resonance imaging (MRI) that reflect small vessel cerebrovascular disease. They are associated with cognitive functioning in older adults and with clinical presentation and course of AD, particularly when distributed in posterior brain regions. The purpose of this study was to examine to what degree regional WMH volume is associated with performance on the primary cognitive outcome measure in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study, a secondary prevention trial.

METHODS

Data from 1791 participants (59.5% women, mean age (SD) 71.6 (4.74)) in the A4 study and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) companion study at the screening visit were used to quantify WMH volumes on T2-weighted fluid-attenuated inversion recovery (FLAIR) MR images. Cognition was assessed with the preclinical Alzheimer cognitive composite (PACC). We tested the association of total and regional WMH volumes with PACC performance, adjusting for age, education, and amyloid positivity status, with general linear models. We also considered interactions between WMH and amyloid positivity status.

RESULTS

Increased frontal and parietal lobe WMH volume was associated with poorer performance on the PACC. While amyloid positivity was also associated with lower cognitive test scores, WMH volumes did not interact with amyloid positivity status.

CONCLUSION

These results highlight the potential of small vessel cerebrovascular disease to drive AD-related cognitive profiles. Measures of small vessel cerebrovascular disease should be considered when evaluating outcome in trials, both as potential effect modifiers and as a possible target for intervention or prevention.

Для цитирования: Morales Clarissa D, Cotton-Samuel Dejania, Lao Patrick J, Chang Julia F, Pyne Jeffrey D, Alshikho Mohamad J, Lippert Rafael V, Bista Kelsang, Hale Christiane, Edwards Natalie C, Igwe Kay C, Deters Kacie, Zimmerman Molly E, Brickman Adam M. Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants.. Alzheimer's research & therapy. 2024. DOI: 10.1186/s13195-024-01395-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.